The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Official Title: Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Study ID: NCT05100095
Brief Summary: This study seeks to determine the safety and efficacy of shortening the primary and nodal adjuvant radiation therapy course from 2 Gy x 25 fractions to 3.6 Gy x 10 fractions in merkel cell carcinoma patients who may or may not be receiving immunotherapy.
Detailed Description: * To estimate the 2-year local control rate for adjuvant hypofractionated RT to the primary tumor bed. * To estimate the 2-year nodal control rate for adjuvant hypofractionated RT to the primary draining nodal basin. Secondary Objectives * To determine MCC disease outcomes including:time to non-nodal locoregional recurrence, time to nodal recurrence, time to distant mestasis, disease-free-survival and disease-specific survival for patients receiving hypofractionated adjuvant RT. * To assess acute and late RT associated toxicity within or neighboring the radiated field.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
M D Anderson Cancer Center, Houston, Texas, United States
Name: Devarati Mitra
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR